Related Experiment Video
Updated: Aug 15, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Albumin-bound and non-protein-bound oestradiol and testosterone in postmenopausal breast disease
S Pearce1, M Dowsett, J A McKinna
1Welsh School of Pharmacy, University of Wales Cardiff College, U.K.
Abstract:
Several studies have recently reported the percentage of non-protein-bound (NPB) oestradiol (E2) to be higher in patients with breast cancer than in normal controls. Using postmenopausal volunteers, we have examined the fractional binding of E2 and testosterone (T), as well as total E2 and T, sex-hormone binding globulin (SHBG), luteinising hormone (LH) and follicle stimulating hormone (FSH), in normal women, those at risk of developing breast cancer and women with breast cancer at first diagnosis and first recurrence. No significant differences were observed in either the concentration or in the percentage of NPB E2 or T, or in any of the other hormones measured. The validity of our observations were confirmed by expected relationships between E2, T, SHBG and body mass.
Related Concept Videos
Oogenesis
Drug Distribution: Tissue Binding
For...
Drug Distribution: Plasma Protein Binding
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...

